By Drug Target Review2024-10-02T12:00:52
Sygnature Discovery has created a platform named SCANME, which can scale up human disease modelling to develop novel therapeutics.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-31T14:05:00Z
2026-03-26T13:58:00Z
2023-07-04T10:05:58
Sponsored by Revvity
2023-02-23T14:02:18
Sponsored by bit.bio
2025-04-02T14:00:00
Sponsored by Eurofins Discovery
2025-07-30T08:00:00
Sponsored by Wuxi Biologics
Site powered by Webvision Cloud